الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - vaktsiinid - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. kasutada shingrix peab olema kooskõlas ametlike soovitustega.

أستونيا - الإستونية - Ravimiamet

chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsioonipulber - 6mcg+200mcg 1annus 120annus 1tk

أستونيا - الإستونية - Ravimiamet

chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsioonipulber - 6mcg+100mcg 1annus 180annus 3tk

أستونيا - الإستونية - Ravimiamet

chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsiooniaerosool, lahus - 6mcg+100mcg 1annus 120annus 1tk; 6mcg+100mcg 1annus 120annus 2tk; 6mcg+100mcg 1annus 180annus 1tk

أستونيا - الإستونية - Ravimiamet

chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsiooniaerosool, lahus - 6mcg+200mcg 1annus 120annus 2tk; 6mcg+200mcg 1annus 180annus 1tk; 6mcg+200mcg 1annus 120annus 1tk

أستونيا - الإستونية - Ravimiamet

chiesi pharmaceuticals gmbh - formoterool+beklometasoon - inhalatsioonipulber - 12mcg+200mcg 1annus 60annus 3tk; 12mcg+200mcg 1annus 60annus 1tk; 12mcg+200mcg 1annus 60annus 2tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - tuulerõugete viirus (elus, nõrgestatud) - herpes zoster; immunization - viiruslikud vaktsiinid - zostavax on näidustatud herpes zoster (zoster'i või kastanite) ja herpes-zoster-ga seotud herpesejärgse neuralgia. zostavax on näidustatud immuniseerimise üksikisikute 50-aastased või vanemad,.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetüülfumaraat - sclerosis multiplex, relapsing-remitting - immunosupressandid - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - erütematoosne luupus, süsteemne - immunosupressandid - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.